Plus   Neg

Pre-market Movers For Nov 8 (JPM, WEN, DF, QCOM, KSS, PANL, SGEN, MNST, CPRX)


JPMorgan Chase & Co. (JPM) is up 2 percent to $41.25. The company disclosed that it has agreed in principle with the staff of the SEC to resolve mortgage-backed securities matters. The Federal Reserve approved the company's resubmitted capital plan, which is related to the repurchase of up to $3.0 billion of common equity in the first quarter of 2013.

Wendy's Co. (WEN) is rising nearly 2 percent to $4.33. The company's third quarter net loss widened from the year-ago quarter, while its adjusted earnings per share from continuing operations were below Wall Street view. Consolidated revenues improved 4.1 percent, but were below the consensus estimate. The company also raised its quarterly cash dividend and authorized a new share repurchase program for up to $100 million of common stock.

Dean Foods Co. (DF) is gaining more than 5 percent to $17.00. The company swung to a profit in its third quarter. However, net sales declined from the year-ago quarter and missed the consensus estimate. Meanwhile, the company lifted its adjusted earnings guidance for full year 2012.

QUALCOMM, Inc. (QCOM) is rising over 8 percent to $63.02 following the release of its fourth quarter results.


Kohl's Corp. (KSS) is falling more than 2 percent to $52.90. The company's third quarter profit improved from the same period a year earlier and was above analysts' estimate. Net sales rose 2.6 percent and topped the consensus estimate. However, the company forecast fourth quarter earnings below analysts' projection and also tightened its full-year earnings per share guidance, which is currently below analysts' expectation.

Universal Display Corp. (PANL) is plunging 25 percent to $21.15, Seattle Genetics Inc. (SGEN) is down 10 percent to $21.99, Monster Beverage Corp. (MNST) is down over 11 percent to $39.91 following the release of their quarterly results.

Catalyst Pharmaceutical Partners Inc. (CPRX) is plunging 64 percent to $0.52. The company announced that U.S. Phase II(b) clinical trial evaluating the use of CPP-109 (vigabatrin) to treat cocaine addiction showed that CPP-109 did not meet the primary endpoint.

Trading halt:

Trading in shares of Rofin-Sinar Technologies Inc. (RSTI) was halted. The company's fourth quarter profit declined 42 percent from the year-ago quarter.

Trading in shares of AMC Networks Inc. (AMCX) was halted. The company's third quarter profit declined from the same period a year earlier.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT